Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
2020 · British Journal of Cancer · 14 citations
https://doi.org/10.1038/s41416-020-0909-4